NCT05106387Recruiting
An Observational Extension Study for Adult Patients Treated in Study R5459-RT-1944 Who Receive a Kidney Transplant
Regeneron Pharmaceuticals
Start Date
10/19/2023
Completion Date
2/23/2028
Summary
The main purpose of this study is to continue to see how vonsetamig works in the body and to monitor the outcomes after kidney transplant for participants previously treated in the R5459-RT-1944 study (NCT05092347). No study drug will be given during this study.
Eligibility Criteria
Age Range: 18 years to 70 years
Inclusion Criteria:
1. Received at least 1 dose of treatment with vonsetamig in study R5459-RT-1944 \[NCT05092347\].
2. Received after acceptable crossmatching, a kidney transplant while enrolled in study R5459-RT-1944
3. Willing and able to comply with clinic visits and study-related procedures
4. Provide informed consent signed by study patient or legally acceptable representative
Exclusion Criteria:
1.There are no exclusion criteria for this study.
Note: Other protocol defined Inclusion/Exclusion criteria may apply
Interventions
DRUG
Noninterventional
Conditions
Chronic Kidney Disease (CKD)
Locations
Cedars-Sinai Medical Center
Los Angeles, California 90048
United States
University of California Irvine
Orange, California 92868
United States
Connie Frank Transplant Center at UCSF
San Francisco, California 94143
United States
Yale University of Medicine
New Haven, Connecticut 06520
United States
Comprehensive Transplant Center
Chicago, Illinois 60611
United States
John Hopkins Hospital
Baltimore, Maryland 21224
United States
University of Minnesota
Minneapolis, Minnesota 55455
United States
New York University Langone Health
New York, New York 10016
United States
Penn Transplant Institute
Philadelphia, Pennsylvania 19104
United States